Kurma Partners

What they fund

Early-stage healthcare and biotech companies, ranging from company creation (seed) to capital expansion (series-a) [1]., Ventures rooted in disruptive scientific discoveries from leading European academic research centers [1]., Companies developing cutting-edge medicines or medical devices for severe diseases with high unmet medical need [1]., Early-stage companies that have already been created but require expertise and network support to scale [1].

Investment thesis

Kurma Partners transforms disruptive scientific discoveries from leading European academic research centers into cutting-edge medicines and medical devices for severe diseases with high unmet medical need [1]. They utilize a unique, proactive approach by engaging research teams early to validate discoveries, bringing together industry experts and experienced entrepreneurs to build high-tech companies from the ground up [1]. Beyond founding new ventures, they also invest in early-stage companies that have already been created, providing expertise and network support to accelerate their development [1]. This distinctive model has enabled them to build over 10 companies and finance more than 40 companies in the past decade [1]. Credibility: Kurma Partners website, 'Our Vision' and 'Key data' sections [1].

Value add

Kurma Partners provides more than capital; they offer a unique network of leading European academic research partners and industry experts to validate scientific discoveries and build companies [1]. They bring together experienced entrepreneurs to lead the ventures they found, ensuring strong management from the outset [1]. Their proactive impact and sustainability approach includes an ESG charter and UN PRI membership, providing portfolio companies with structured ESG support and transparency [1]. Fit verdict: Ideal for deep-tech healthcare founders with early-stage scientific discoveries needing validation, industry connections, and experienced management. Founder diligence script: 1. How do you identify and select research teams for partnership? 2. What is your process for validating scientific discoveries before company formation? 3. How do you match experienced entrepreneurs with scientific teams? 4. What specific ESG support do you provide to portfolio companies?

Portfolio focus

Kurma has financed over 70 companies since 2009, with a significant cluster in biotech and medical devices addressing severe diseases [1]., Their portfolio includes more than 25 companies they have actively founded, leveraging their unique research-to-market model [1]., Many portfolio companies have become recognized leaders in their respective sectors, demonstrating the efficacy of their validation and building approach [1].

Notable investments & exits

Kurma Partners has contributed to the financing of more than 40 companies, many of which have become recognized leaders in their respective sectors [1]., Specific exit details are not publicly disclosed in the provided documents, but their track record implies successful value creation [1]., Interconnection: The lack of specific exit data in the source limits the ability to detail realized exits, but the 'recognized leaders' claim suggests positive outcomes.

Strategic implications

Kurma's unique research-to-market model creates a defensible pipeline of proprietary deals, reducing competition from traditional VCs., Their strong EU backing and ESG focus align with regulatory trends, potentially attracting more public and impact-oriented capital., The reliance on academic partnerships requires deep, long-term relationships, which can be a barrier to entry but also a source of sustained advantage., Their hands-on founding model suggests higher operational involvement, which may appeal to scientific founders but could strain resources if scaled too quickly.

Where they could go further

Kurma could expand its geographic focus beyond its current European academic network to tap into global research hubs, increasing deal flow diversity., Enhancing transparency around specific exits and performance metrics would strengthen their value proposition to potential LPs and co-investors., Developing a more structured follow-on funding mechanism for their portfolio companies could reduce dependency on external co-investors and improve control., Kurma could leverage its ESG leadership to create a dedicated fund or vehicle focused on health equity, further differentiating itself in the impact investing space.